Novo Medi Sciences Launches Nexipox Plus, India-Specific Upgraded Varicella Vaccine

Novo Medi Sciences Pvt. Ltd. has launched Nexipox Plus, a next-generation varicella (chickenpox) vaccine developed specifically for Indian clinical and operational conditions.

The company positions Nexipox Plus as the first proactive upgrade of varicella vaccine designed for India, addressing stability, safety, and immunogenicity challenges seen in real-world use.

Why varicella vaccines need formulation innovation?

Live attenuated varicella vaccines are thermolabile, meaning they are sensitive to heat. This makes stability and potency retention critical, especially in countries with:

• Hot climates
• Variable cold-chain infrastructure
• High patient volumes

Nexipox Plus introduces a 2X trehalose-based stabiliser system to improve formulation robustness.

What makes Nexipox Plus different?

The vaccine replaces conventional stabilisers such as gelatin and mannitol with trehalose. This shift delivers several advantages:

• Enhanced viral stability
• Better potency preservation
• Reduced risk of allergic reactions
• Lower chance of antigen crystallisation

The result is more consistent vaccine performance during storage, transport, and administration.

Clinical data shows strong immune response

Clinical studies in Indian patients demonstrated:

• 98% seroconversion after a two-dose schedule
• 35.4-fold geometric mean rise in antibody titres

“These results indicate a robust immune response and effective protection,” said Forum Bhagat, Managing Director, Novo Medi Sciences.

Favourable safety profile

In comparative clinical trials:

• No serious adverse events were causally linked to Nexipox Plus
• Removal of gelatin further supports improved tolerability

This strengthens its suitability for routine immunisation.

Expert perspective on clinical relevance

Dr Nitin K. Shah, Consultant Paediatrician and Paediatric Hemato-Oncologist, Mumbai, highlighted:

• Enhanced immunogenicity as the key clinical advance
• More consistent immune responses due to improved formulation
• Increased clinician confidence in routine practice

Supporting India’s immunisation priorities

Chickenpox remains prevalent in India. Nexipox Plus is designed to support:

• Higher vaccination compliance
• Affordable and scalable deployment
• Adoption in private and institutional settings

The vaccine is approved by DCGI for use from 12 months of age.

Built for future global expansion

Nexipox Plus is backed by patented technology across 156 countries. Novo Medi Sciences is evaluating international expansion based on:

• Public health need
• Sustainable supply planning

Bottom line

With Nexipox Plus, Novo Medi Sciences advances formulation-led vaccine innovation, delivering improved stability, safety, and immunogenicity tailored to Indian healthcare realities.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!